However, the recent updates of PARP inhibitors as maintenance therapy seem more promising.128–132 For example, in BRCA mutant ovarian cancer patients responsive to first-line platinum-based chemotherapy,133 olaparib maintenance therapy prolonged both mPFS (56.0 vs 13.8 months, hazard ratio: 0.33) and mOS (not reached vs 75.2 months, hazard ratio: 0.55) than placebo control. This evidence concerns the gene PARP1 and ovarian cancer.